Calando Says Strength of Phase I Trial of CALAA-01 Will Attract Partners, Including Suitors

Although in the short term it will continue to focus on CALAA-01, the siRNA-based drug expected to create partnerships for Calando, Arrowhead is considering initiating new drug-development programs.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.